propafenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiarrhythmics, propafenone derivatives	2291	54063-53-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: propafenone propafenone hydrochloride polfenon (RS)-Propafenone propafenone HCl	An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Molecular weight: 341.45 Formula: C21H27NO3 CLOGP: 3.64 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 58.56 ALOGS: -4.65 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

propafenone
propafenone hydrochloride
polfenon
(RS)-Propafenone
propafenone HCl

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.

Molecular weight: 341.45
Formula: C21H27NO3
CLOGP: 3.64
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 58.56
ALOGS: -4.65
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.30	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.09 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	12 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 27, 1989	FDA	GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Atrial fibrillation	188.59	17.49	143	7731	101602	50495648
Electrocardiogram QRS complex prolonged	155.81	17.49	50	7824	5294	50591956
Bradycardia	138.25	17.49	99	7775	64327	50532923
Drug interaction	126.21	17.49	155	7719	199466	50397784
Sinus bradycardia	105.52	17.49	48	7826	13135	50584115
Arrhythmia	64.37	17.49	48	7826	33084	50564166
Cardiac arrest	60.99	17.49	70	7804	83581	50513669
Completed suicide	55.16	17.49	84	7790	131805	50465445
Enzyme induction	52.56	17.49	9	7865	53	50597197
Syncope	50.90	17.49	71	7803	102931	50494319
Toxicity to various agents	50.89	17.49	106	7768	212393	50384857
Intentional overdose	48.42	17.49	54	7820	62450	50534800
Atrioventricular block complete	44.49	17.49	22	7852	7233	50590017
Palpitations	43.52	17.49	63	7811	94443	50502807
Atrial flutter	43.38	17.49	23	7851	8740	50588510
Cardiogenic shock	42.94	17.49	28	7846	15571	50581679
Hypotension	41.43	17.49	104	7770	235365	50361885
Asthenia	40.44	17.49	125	7749	318917	50278333
Bradyarrhythmia	40.39	17.49	14	7860	1876	50595374
International normalised ratio increased	36.39	17.49	39	7835	43113	50554137
Dizziness	36.10	17.49	127	7747	346242	50251008
Systolic dysfunction	35.74	17.49	12	7862	1460	50595790
Nodal arrhythmia	34.74	17.49	11	7863	1113	50596137
Ventricular tachycardia	33.14	17.49	24	7850	15797	50581453
Generalised tonic-clonic seizure	31.91	17.49	29	7845	26281	50570969
Loss of consciousness	29.67	17.49	56	7818	104297	50492953
Electrocardiogram abnormal	29.50	17.49	17	7857	7588	50589662
Tension	28.39	17.49	12	7862	2750	50594500
Cardiac assistance device user	27.34	17.49	5	7869	45	50597205
Bradykinesia	27.32	17.49	13	7861	3930	50593320
Atrioventricular block first degree	27.14	17.49	15	7859	6186	50591064
Bundle branch block left	27.07	17.49	15	7859	6215	50591035
Labelled drug-drug interaction medication error	26.88	17.49	18	7856	10459	50586791
Coagulation test abnormal	26.76	17.49	8	7866	668	50596582
Granulocytopenia	26.65	17.49	14	7860	5217	50592033
Haemodynamic instability	26.07	17.49	16	7858	8008	50589242
Duplicate therapy error	25.73	17.49	5	7869	64	50597186
Flat affect	25.33	17.49	9	7865	1296	50595954
Conduction disorder	25.31	17.49	9	7865	1299	50595951
Pain	25.17	17.49	32	7842	578871	50018379
Suicide attempt	24.54	17.49	35	7839	51697	50545553
Product dispensing issue	24.30	17.49	5	7869	87	50597163
Defect conduction intraventricular	23.36	17.49	5	7869	106	50597144
Product measured potency issue	23.32	17.49	5	7869	107	50597143
Psychomotor retardation	22.86	17.49	11	7863	3407	50593843
Brugada syndrome	22.62	17.49	6	7868	324	50596926
Periorbital haematoma	21.99	17.49	7	7867	720	50596530
Noninfective gingivitis	21.96	17.49	8	7866	1238	50596012
Ischaemic hepatitis	21.91	17.49	9	7865	1920	50595330
Atrioventricular block	21.26	17.49	13	7861	6465	50590785
Rhythm idioventricular	21.04	17.49	5	7869	172	50597078
Metabolic acidosis	21.01	17.49	28	7846	38797	50558453
Diastolic dysfunction	20.96	17.49	12	7862	5290	50591960
Overweight	20.85	17.49	10	7864	3076	50594174
N-terminal prohormone brain natriuretic peptide	20.75	17.49	4	7870	49	50597201
Tachycardia	20.65	17.49	47	7827	99716	50497534
Brain oedema	19.82	17.49	16	7858	12354	50584896
Overdose	19.56	17.49	46	7828	99681	50497569
Sinus arrest	19.55	17.49	8	7866	1690	50595560
pH body fluid abnormal	19.05	17.49	4	7870	77	50597173
Cardioversion	18.88	17.49	7	7867	1138	50596112
Myocardial ischaemia	18.56	17.49	15	7859	11598	50585652
Drug-disease interaction	17.76	17.49	5	7869	338	50596912

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged	236.68	18.37	66	4858	4044	29565559
Bradycardia	115.61	18.37	92	4832	65537	29504066
Electrocardiogram PR prolongation	108.31	18.37	25	4899	706	29568897
Atrial fibrillation	85.14	18.37	96	4828	105550	29464053
Facial asymmetry	59.59	18.37	13	4911	282	29569321
Drug interaction	57.60	18.37	111	4813	197274	29372329
Ventricular tachycardia	56.13	18.37	39	4885	22535	29547068
Palpitations	47.46	18.37	41	4883	32563	29537040
Accidental exposure to product by child	39.95	18.37	13	4911	1341	29568262
Neonatal pneumonia	39.03	18.37	8	4916	127	29569476
Neonatal hypotension	37.87	18.37	8	4916	148	29569455
Atrioventricular block first degree	37.13	18.37	18	4906	5301	29564302
Dry mouth	32.91	18.37	28	4896	21756	29547847
Atrial flutter	32.18	18.37	23	4901	13871	29555732
Dizziness	31.03	18.37	85	4839	189599	29380004
Brugada syndrome	30.23	18.37	9	4915	692	29568911
Heart rate irregular	26.51	18.37	20	4904	13097	29556506
Drug level increased	26.06	18.37	23	4901	18764	29550839
Arrhythmia	26.04	18.37	29	4895	31284	29538319
Accidental overdose	25.33	18.37	22	4902	17571	29552032
Speech disorder	25.31	18.37	25	4899	23491	29546112
Nodal arrhythmia	25.14	18.37	8	4916	768	29568835
Bundle branch block right	25.08	18.37	15	4909	6702	29562901
Electrocardiogram QT prolonged	24.28	18.37	30	4894	36107	29533496
Completed suicide	24.07	18.37	49	4875	90197	29479406
Respiratory disorder neonatal	23.97	18.37	9	4915	1416	29568187
Transient ischaemic attack	23.68	18.37	24	4900	23246	29546357
Syncope	22.67	18.37	45	4879	81326	29488277
Cholestatic liver injury	22.44	18.37	9	4915	1688	29567915
Generalised tonic-clonic seizure	21.82	18.37	21	4903	19118	29550485
Ventricular arrhythmia	21.79	18.37	12	4912	4592	29565011
Trifascicular block	19.79	18.37	4	4920	59	29569544
Sinus bradycardia	19.78	18.37	16	4908	11587	29558016
Loss of consciousness	19.48	18.37	40	4884	74016	29495587
Cardiac flutter	19.16	18.37	8	4916	1662	29567941
Presyncope	18.99	18.37	18	4906	16071	29553532
Sopor	18.47	18.37	15	4909	10919	29558684

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged	373.17	15.51	115	11614	9129	64477874
Bradycardia	212.35	15.51	174	11555	118045	64368958
Atrial fibrillation	191.48	15.51	193	11536	170896	64316107
Drug interaction	159.02	15.51	256	11473	361827	64125176
Sinus bradycardia	101.72	15.51	59	11670	22834	64464169
Electrocardiogram PR prolongation	99.46	15.51	27	11702	1360	64485643
Ventricular tachycardia	82.24	15.51	60	11669	34205	64452798
Palpitations	69.20	15.51	90	11639	104398	64382605
Completed suicide	67.70	15.51	135	11594	224279	64262724
Arrhythmia	66.99	15.51	64	11665	52880	64434123
Atrial flutter	65.66	15.51	42	11687	19338	64467665
Atrioventricular block first degree	62.31	15.51	33	11696	10701	64476302
Syncope	60.23	15.51	105	11624	157530	64329473
Cardiac arrest	56.76	15.51	101	11628	153963	64333040
Generalised tonic-clonic seizure	53.89	15.51	50	11679	39807	64447196
Toxicity to various agents	53.38	15.51	166	11563	363347	64123656
Nodal arrhythmia	50.10	15.51	17	11712	1826	64485177
Dizziness	48.68	15.51	180	11549	429983	64057020
Facial asymmetry	47.29	15.51	13	11716	686	64486317
Brugada syndrome	45.96	15.51	14	11715	1064	64485939
Enzyme induction	45.61	15.51	9	11720	106	64486897
Intentional overdose	39.77	15.51	64	11665	89880	64397123
Bundle branch block right	39.17	15.51	24	11705	10245	64476758
Retro-orbital neoplasm	38.74	15.51	7	11722	49	64486954
Loss of consciousness	38.52	15.51	84	11645	148281	64338722
Hypotension	37.01	15.51	152	11577	380822	64106181
Conduction disorder	35.42	15.51	15	11714	2953	64484050
Neonatal pneumonia	34.61	15.51	6	11723	32	64486971
Neonatal hypotension	34.61	15.51	6	11723	32	64486971
International normalised ratio increased	34.54	15.51	56	11673	79111	64407892
Asthenia	33.41	15.51	160	11569	427884	64059119
Electrocardiogram abnormal	33.22	15.51	24	11705	13457	64473546
Heart rate irregular	32.51	15.51	32	11697	27381	64459622
Bradyarrhythmia	32.02	15.51	15	11714	3743	64483260
Atrioventricular block complete	31.78	15.51	24	11705	14394	64472609
Respiratory disorder neonatal	31.21	15.51	6	11723	61	64486942
Accidental exposure to product by child	31.13	15.51	13	11716	2472	64484531
Drug level increased	30.01	15.51	34	11695	34162	64452841
Electrocardiogram QT prolonged	29.11	15.51	52	11677	79396	64407607
Cardiogenic shock	28.05	15.51	32	11697	32395	64454608
Bundle branch block left	27.36	15.51	19	11710	10015	64476988
Pain	25.81	15.51	38	11691	553473	63933530
Cardiac assistance device user	25.10	15.51	5	11724	62	64486941
Systolic dysfunction	24.90	15.51	12	11717	3190	64483813
Muscle mass	24.82	15.51	7	11722	406	64486597
Product dispensing issue	23.25	15.51	5	11724	92	64486911
Tension	22.83	15.51	12	11717	3828	64483175
Sinus arrest	22.28	15.51	11	11718	3079	64483924
Arthralgia	21.96	15.51	29	11700	442231	64044772
Coagulation test abnormal	21.58	15.51	8	11721	1111	64485892
Flat affect	20.89	15.51	9	11720	1848	64485155
Supraventricular tachycardia	20.45	15.51	21	11708	18886	64468117
Myocardial ischaemia	20.20	15.51	23	11706	23228	64463775
Ventricular arrhythmia	20.12	15.51	14	11715	7401	64479602
Noninfective gingivitis	20.10	15.51	8	11721	1346	64485657
Atrioventricular block	20.07	15.51	17	11712	11998	64475005
Rheumatoid arthritis	20.01	15.51	3	11726	164291	64322712
Small for dates baby	20.00	15.51	6	11723	433	64486570
N-terminal prohormone brain natriuretic peptide	19.83	15.51	4	11725	53	64486950
Presyncope	19.81	15.51	28	11701	35061	64451942
Periorbital haematoma	19.49	15.51	7	11722	889	64486114
Duplicate therapy error	19.46	15.51	5	11724	203	64486800
Bradykinesia	19.25	15.51	13	11716	6547	64480456
Rhythm idioventricular	18.96	15.51	6	11723	517	64486486
Haemodynamic instability	18.79	15.51	18	11711	14894	64472109
Low birth weight baby	18.58	15.51	6	11723	552	64486451
Cardio-respiratory arrest	18.30	15.51	49	11680	98344	64388659
Cholestatic liver injury	17.72	15.51	10	11719	3669	64483334
Transient ischaemic attack	17.58	15.51	30	11699	44152	64442851
Psychomotor retardation	17.05	15.51	11	11718	5132	64481871
Suicide attempt	17.05	15.51	39	11690	70968	64416035
Defect conduction intraventricular	16.75	15.51	5	11724	355	64486648
pH body fluid abnormal	16.67	15.51	4	11725	122	64486881
Atrial thrombosis	16.66	15.51	9	11720	3033	64483970
Dry mouth	16.56	15.51	35	11694	60383	64426620
Overdose	16.50	15.51	65	11664	159501	64327502
Rash	16.41	15.51	37	11692	458512	64028491
Tachycardia	16.33	15.51	62	11667	149517	64337486
Labelled drug-drug interaction medication error	16.15	15.51	20	11709	22042	64464961
Ischaemic hepatitis	16.11	15.51	9	11720	3237	64483766
Granulocytopenia	15.88	15.51	14	11715	10426	64476577
Overweight	15.86	15.51	9	11720	3337	64483666
Trifascicular block	15.85	15.51	4	11725	151	64486852
Diastolic dysfunction	15.74	15.51	13	11716	8862	64478141
Exophthalmos	15.73	15.51	7	11722	1553	64485450

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01BC03	CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ic
FDA EPC	N0000175426	Antiarrhythmic
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026941	Sodium Channel Blockers
MeSH PA	D061567	Voltage-Gated Sodium Channel Blockers
CHEBI has role	CHEBI:38070	antiarrhythmic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atrial fibrillation	indication	49436004	DOID:0060224
Paroxysmal supraventricular tachycardia	indication	67198005
Paroxysmal atrial fibrillation	indication	282825002
Paroxysmal atrial flutter	indication	427665004
Life-Threatening Ventricular Tachycardia	indication
Cardioversion of Atrial Fibrillation	off-label use
Bronchospasm	contraindication	4386001
Bundle branch block	contraindication	6374002
Hyperkalemia	contraindication	14140009
Agranulocytosis	contraindication	17182001	DOID:12987
Myocardial infarction	contraindication	22298006	DOID:5844
Torsades de pointes	contraindication	31722008
Sick sinus syndrome	contraindication	36083008	DOID:13884
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Prolonged QT interval	contraindication	111975006
Structural disorder of heart	contraindication	128599005
Atrioventricular block	contraindication	233917008	DOID:0050820
Disease of liver	contraindication	235856003	DOID:409
Severe chronic obstructive pulmonary disease	contraindication	313299006
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN	BLOCKER	IC50	5.48	CHEMBL	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	6.69	DRUG MATRIX	CHEMBL
Sodium channel subunit beta-1	Ion channel	Q07699	SCN1B_HUMAN				WOMBAT-PK
Sodium channel subunit beta-2	Ion channel	O60939	SCN2B_HUMAN				WOMBAT-PK
Sodium channel subunit beta-3	Ion channel	Q9NY72	SCN3B_HUMAN				WOMBAT-PK
Sodium channel subunit beta-4	Ion channel	Q8IWT1	SCN4B_HUMAN				WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.96	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.10	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		ED50	7.06	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.52	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.03	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.73	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.24	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.70	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.06	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.60	WOMBAT-PK
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	6.50	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.83	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5.34	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.60	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.48	DRUG MATRIX
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN		IC50	5.12	CHEMBL
Potassium voltage-gated channel subfamily A member 5	Ion channel	P22460	KCNA5_HUMAN	BLOCKER	IC50	4.40	IUPHAR
Potassium channel subfamily K member 3	Ion channel	O14649	KCNK3_HUMAN		IC50	5.29	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.95	CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Ion channel	Q9Y3Q4	HCN4_HUMAN		IC50	4.85	WOMBAT-PK
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.60	WOMBAT-PK
Sulfonylurea receptor 2, Kir6.2	Ion channel	O60706 Q14654	ABCC9_HUMAN KCJ11_HUMAN		IC50	5.66	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	7.44	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.85	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	5.21	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.79	CHEMBL

External reference:

ID	Source
4019911	VUID
N0000147996	NUI
D00640	KEGG_DRUG
34183-22-7	SECONDARY_CAS_RN
4019487	VANDF
4019911	VANDF
C0033429	UMLSCUI
CHEBI:63619	CHEBI
CHEMBL631	ChEMBL_ID
DB01182	DRUGBANK_ID
CHEMBL1201063	ChEMBL_ID
D011405	MESH_DESCRIPTOR_UI
4932	PUBCHEM_CID
2561	IUPHAR_LIGAND_ID
3312	INN_ID
68IQX3T69U	UNII
203135	RXNORM
40681	MMSL
40682	MMSL
5368	MMSL
d00358	MMSL
003525	NDDF
004487	NDDF
108501006	SNOMEDCT_US
372910007	SNOMEDCT_US
96300001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0823	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0824	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0826	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	NDA	29 sections
Propafenone HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0582	TABLET, FILM COATED	150 mg	ORAL	ANDA	29 sections
Propafenone HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0583	TABLET, FILM COATED	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2285	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2286	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2287	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5448	TABLET, FILM COATED	150 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5449	TABLET, FILM COATED	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5450	TABLET, FILM COATED	300 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0740	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0741	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0742	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	30 sections
PROPAFENONE HYDROCHLORIDE	Human Prescription Drug Label	1	16571-736	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	30 sections
PROPAFENONE HYDROCHLORIDE	Human Prescription Drug Label	1	16571-737	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	30 sections
PROPAFENONE HYDROCHLORIDE	Human Prescription Drug Label	1	16571-738	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	30 sections
propafenone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-825	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
propafenone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-826	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections
propafenone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-827	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	29 sections
Propafenone	HUMAN PRESCRIPTION DRUG LABEL	1	21695-814	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	21 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24979-085	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24979-086	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24979-087	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-545	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-546	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-547	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	49884-113	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	49884-113	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	49884-210	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections